Policy and Regulation · 2 October 2026 to 2 October 2026 · 1 headlines · MedCity News
Pfizer Pill’s Phase 3 Data in Vitiligo Pave Way for FDA, EMA Submissions
Pfizer's Phase 3 data on its vitiligo pill has positioned the company to move forward with regulatory submissions to the FDA and EMA.
As it ran
2 October 2026
More from US healthcare
- RFK Jr. throws fuel on intensifying debate over healthcare AI 2 October 2026
- Pennsylvania announces 5th measles-related death as cases approach 1,000 2 October 2026
- Medicaid work requirements legal challenges 2 October 2026
- CMS 340B claims data initiative 2 October 2026
- HRSA's 340B Rebate Model Pilot Program 2 October 2026
- AHA comments to MedPAC on differences in post-acute care use between MA, fee-for-service Medicare beneficiaries 2 October 2026
- AHA, others file amicus brief supporting hospital in challenge to Lilly 340B policy 2 October 2026
- Hospitals expand push to limit ER visits ahead of Medicaid cuts 2 October 2026